News Releases
Click here to access press releases from Astellas Pharma Inc. located in Tokyo, Japan.
-
Feb 18, 2021- Submissions will be Reviewed Under Real-Time Oncology Review Based on Clinical Trials EV-301 and Cohort 2 of EV-201 -
-
Feb 12, 2021- Durable Tumor Responses Experienced Among Patients Previously Treated with Immunotherapy in Second Cohort of EV-201 Trial -
-
Feb 12, 2021- Findings from the EV-301 Trial Showed Significant Improvements in Overall Survival and Progression-Free Survival Compared to Chemotherapy -
-
Feb 4, 2021Oncology head Mark Reisenauer named Astellas US President; Masahide Goto named President at Astellas Institute for Regenerative Medicine
-
Feb 3, 2021- Accelerated approval follows priority review designation and inclusion in overseas new drugs urgently needed in clinical settings
-
Dec 14, 2020Sponsorship provides a year of access to MBC BioLabs' life-science incubators and in-house Astellas expertise
-
Nov 27, 2020Approval by MHLW provides new HIF-PH inhibitor treatment option for healthcare providers and adult patients with anemia of CKD not on dialysis
-
Nov 16, 2020Includes five oral presentations that collectively explore the use of gilteritinib across the FLT3mut+ AML care continuum
-
Nov 6, 2020Enzalutamide is now NMPA-approved for both non-metastatic and metastatic castration-resistant prostate cancer
-
Oct 19, 202042 abstracts featuring additional insights into roxadustat and anemia of chronic kidney disease to be presented
-
Oct 12, 2020- Durable Responses Observed in Patients Who Had Previously Received Immunotherapy but Were Ineligible for Cisplatin in Locally Advanced or Metastatic Setting -
-
Oct 8, 2020- AXONIS Therapeutics, Inc. and Tenza win a year of access to life-science incubator in Cambridge, MA and access to Astellas expertise to further their research -
-
Oct 1, 2020- 11th Annual Changing Tomorrow Day Enables Employees to Support Frontline Workers in Hospitals, Homeless and Hospitalized Veterans and Others in Need -
-
Sep 29, 2020Sponsorship provides a year of access to MBC BioLabs' life-science incubators and in-house Astellas expertise for scientific innovators
-
Sep 28, 2020New findings to be presented at The North American Menopause Society (NAMS) 2020 Virtual Annual Meeting
-
Sep 18, 2020- Trial Stopped Early Due to Positive Results at Planned Interim Analysis -
-
Sep 1, 2020Recent grants and redirected funding help to respond to the COVID-19 pandemic by improving healthcare infrastructure, training and education in low-income countries
-
Aug 4, 2020-Tackling everyday challenges in cancer care, apply by September 28, 2020-
-
Jul 23, 2020Astellas "Golden Ticket" sponsorship provides access to life-science incubator and in-house Astellas expertise for scientific entrepreneurs with cutting-edge ideas
-
Jun 8, 2020- Study meets primary endpoint demonstrating non-inferiority of roxadustat to darbepoetin in correction and maintenance of hemoglobin levels
-
May 29, 2020Data simultaneously published in the New England Journal of Medicine and presented during the virtual scientific program of the 2020 ASCO Annual Meeting
-
May 29, 2020XTANDI is now MHLW-approved for both metastatic hormone-sensitive prostate cancer and castration-resistant prostate cancer in Japan
-
May 20, 2020Submission for the treatment of anemia in adult patients with chronic kidney disease
-
Feb 19, 2020- Breakthrough Therapy Designation Based on Initial Results from Phase 1b/2 EV-103 Clinical Trial -
-
Feb 10, 2020- After Median Follow-Up of 11.5 Months, 73 Percent of Patients Had Confirmed Tumor Response with Majority of Responses Still Ongoing; No New Safety Signals Observed for the Combination - - Findings To Be Presented During an Oral Session at the 2020 Genitourinary Cancers Symposium -
-
Feb 10, 2020- New Funding will Address Disparities in Mental Health Diagnosis and Treatment for 400,000 People in Need -
-
Jan 15, 2020- Combined company positioned to become a global leader in AAV-based genetic medicines, with Audentes to operate as a wholly-owned subsidiary and Center of Excellence for Astellas' newly created Genetic Regulation Primary Focus
-
Dec 26, 2019Acquisition adds talent and proprietary therapeutic platform to accelerate next-generation cancer immunotherapy
-
Dec 18, 2019- First-in-Class Antibody-Drug Conjugate Directed Against Nectin-4, a Protein Highly Expressed in Urothelial Tumors1,2 -
-
Dec 16, 2019XTANDI is Now FDA-Approved for the Treatment of Metastatic Castration-Sensitive Prostate Cancer in Addition to Non-Metastatic and Metastatic Castration-Resistant Prostate Cancer
-
Dec 9, 2019Catherine Levitt and Charlotte Stanton named to key global and regional senior roles
-
Dec 5, 2019Two exciting biotechs win a year of access to life-science incubator and in-house Astellas expertise to advance their early drug discovery research
-
Dec 2, 2019Emerging mutations in patients with treatment resistance, from Phase 3 ADMIRAL study, will be focus of oral presentation
-
Dec 2, 2019- Companies to Initiate Phase 3 Trial to Support Global Registrations -